Skip to main content
Equibles
INMB logo

INMB · Inmune Bio, Inc. · Metrics

Track INMB — free

Use INMB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INMB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.46 -0.08 (-5.19%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$40.52M
Shares
27.75M
Volume · Oct 23 190.56K Avg daily vol (3M) 327.36K

INMB metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.46
Market cap
$40.52M

Price action

20 metrics
Price change (1W)
-7.0%
Price change (30D)
-27.0%
Price change (3M)
-9.9%
Price change (6M)
+5.0%
Price change (YTD)
-6.4%
Price change (1Y)
-18.4%
Trailing year
Price change (5Y)
-92.7%
52-week high
$2.51
52-week low
$1.12
Change from 52-week high
-41.8%
Change from 52-week low
+30.4%
Annualized volatility
73.3%
Annualized volatility (3M)
65.1%
Beta
2.5
RSI (14D)
28.4
Price vs SMA 50
-29.1%
Price vs SMA 200
-10.8%
Avg volume (3M)
327,356
Relative volume
0.6
Average dollar volume
$671,058

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
27.75M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.1
reciprocal yield 47.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-43.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1,096.3×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
983.0×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-31

Profitability

9 metrics
Gross margin
—
Operating margin
-94,766.0%
Trailing 12 months
Net margin
-91,866.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$20.20M
Net income (TTM)
−$18.42M
Trailing 12 months
Diluted EPS (TTM)
$-0.63
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.76
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.69
Operating cash flow per diluted share (TTM)
$-0.56
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.66
Stock compensation per diluted share (TTM)
$0.34
Book value per share
$0.88

Growth

11 metrics
Revenue growth YoY
+257.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.7%
Year over year · more shares
Revenue CAGR (3Y)
-48.9%
Revenue CAGR (5Y)
+35.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-90.4%
Return on assets
-68.6%
Debt / equity
0.5
Current ratio
4.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$18.37M
Latest balance sheet
Cash & equivalents
$18.41M
Total assets
$26.84M
Total debt
$15.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.96M
Capital expenditures (TTM)
—
R&D (TTM)
$16.66M
SG&A (TTM)
—
Stock compensation (TTM)
$9.15M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
82
13F filer change QoQ
-1
Institutional ownership
16.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
6.2%
Private-fund adviser ownership
4.9%
Active holders' share change QoQ
+32.7%
Holder tenure
6.6
Price vs estimated holder cost
-42.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.1%

Short interest

3 metrics
Short interest
9.6%
Latest settlement · 7.0 days to cover
Days to cover
7.0d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1711754 CUSIP 45782T105 13F (30d) 7 filings 7 filers Visit website Investor relations